Sector News

Henrik Stenqvist joins Sobi as CFO

February 26, 2018
Life sciences

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that Henrik Stenqvist will be appointed Chief Financial Officer (CFO) and will join Sobi in late spring. Henrik will be a member of Sobi’s Executive Committee.

Henrik Stenqvist has comprehensive experience from the pharmaceutical industry with 25 years in finance and management positions. He joins Sobi from a position as CFO of Recipharm. Prior to that, Henrik Stenqvist served as the CFO of the Meda Group, where he played an instrumental role in the transformation of Meda from a small Nordic player to a leading international specialty pharma, executing numerous acquisitions as well as the integration of these.

Henrik Stenqvist holds a degree in Finance and Business Administration from the University of Linköping, Sweden.

“It is a pleasure to welcome Henrik to Sobi. His experience from the pharmaceutical industry and specifically from acquisitions and deal making in specialty pharma will be of immense value for Sobi on our journey to become a global leader in rare diseases and specialty care”, says Guido Oelkers, CEO and President of Sobi.

“I am very happy to be joining Sobi and I believe that I, through my experience, can contribute to realising Sobi’s growth strategy”, says Henrik Stenqvist.

Sobi’s current CFO, Mats-Olof Wallin, will support the transition process and will retire by year-end 2018. Mats-Olof Wallin has been an important contributor in the management of Sobi and for the Group to become a company with healthy top-line and earnings growth.

Source: Sobi

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.